Effect of Pioglitazone on Fibrinolyic Factors and Markers of Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus.
|
Accession number;01A0882618
|
| Title;Effect of Pioglitazone on Fibrinolyic Factors and Markers of Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus. |
| Author;
KUBO KEIJI
(Hiroshimabyoin Naibumpitsunaika)
|
Journal Title;Journal of the Japan Diabetic Society
|
Journal Code:Z0279B
|
ISSN:0021-437X
|
|
VOL.44;NO.8;PAGE.687-692(2001)
|
| Figure&Table&Reference;FIG.2, TBL.1, REF.20 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We studied the effect of Pioglitazone (Pio) on fibrinolyiic and endothelial function in type 2 diabetes mellitus. Subjects were 56 patients with type 2 diabetes mellitus-12 men and 44 women aged 47-76 years (mean: 64.1 years)-. Of these, 18 were treated with Pioglitazone alone (PI group), 12 with Gliclazide (Gli) alone (GL group), and 26 with Pioglitazone plus Gliclazide (PG group) for 12 weeks. Fasting blood samples were collected before and after administration to measure fasting plasma glucose (FPG), immunoreactive insulin (IRI), plasminogen activator inhibitor 1(PAI-1), and von Willebrand factor (vWF) as a marker of endothelial dysfunction. In the PI and PG groups, PAI-1 and vWF were significantly decreased after treatment with Pio, with significant decr eases also seen in FPG and IRI. In the GL group, FPG decreased significantly and IRI increased significantly following administration of Gli, while PAI-1 and vWF were unchanged. These results suggest that Pio therapy for patients with type 2 diabetes mellitus is beneficial to the fibrinolyiic system and vascular endothelial function, and controls hyperglycemia and ameliorating hyperinsulinemia. (author abst.) |
|
|
|
Related Articles;
|
|
